Paradoxically, patients with EGFR mutations are reported to have lower PD‐L1 expression and tumor mutational burden (TMB), leading to poor response to anti‐PD‐1/PD‐L1 inhibitors.22, 23. The gene discussed is EGFR; the disease is neoplasm.